About Lenvatinib Mesylate (Form C And MIBK Solvate) API
Therapeutic Category Oncology
CAS Number
857890-39-2
API Technology
Prostaglandins
Dose Form
Oral Solid/Capsules
Dr Reddy's Development Status
Available
Available Regulatory Filing
USDMF, Brazil DMF, Canada DMF, Korea DMF
Mechanism of Action
Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET
Indication
envatinib is indicated for the treatment of the following cancerous conditions:5
Differentiated Thyroid Cancer (DTC)
- Treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer
Renal Cell Carcinoma (RCC)
- First-line treatment, in combination with pembrolizumab, in adult patients with advanced renal cell carcinoma (RCC)
- Treatment of advanced renal cell carcinoma, in combination with everolimus, in adult patients who have previously tried ≥1 anti-angiogenic therapy
Hepatocellular Carcinoma (HCC)
- First-line treatment of patients with unresectable hepatocellular carcinoma
Endometrial Carcinoma
- Treatment of advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), in combination with pembrolizumab, in patients who have experienced disease progression following prior systemic therapy and are not candidates for curative surgery or radiation
Request for Quotation
Get in touch with us by filling out the form below. Our team will reach out to you shortly!
Related APIs
Adagrasib
Oncology
Tucatinib
Oncology
Ripretinib
Oncology
Cabozantinib Hydrochloride
Oncology
Cabozantinib S-Malate
Oncology
Acalabrutinib
Oncology
Capivasertib
Oncology
Lenvatinib Mesylate (Form C and MIBK Solvate)
Oncology
Azacitidine
Oncology
Bendamustine Hydrochloride
Oncology
Relugolix
Oncology
Bortezomib
Oncology
Cabazitaxel
Oncology
Capecitabine
Oncology
Pomalidomide
Oncology
Pemetrexed Disodium Heptahydrate
Oncology
Pazopanib
Oncology
Palbociclib
Oncology
Dasatinib (Monohydrate)
Anti-Cancer/ Oncology
Olaparib (Form A)
Oncology
Decitabine
Oncology
Nilotinib Hydrochloride Monohydrate (Form B)
Oncology
Midostaurin (Amorphous and Form II)
Oncology
Enzalutamide (Crystalline & Premix)
Oncology
Eribulin Mesylate
Oncology
Gemcitabine Hydrochloride
Oncology
Lenalidomide (Form A)
Oncology
Lomustine
Oncology
Abiraterone Acetate
Oncology
Apalutamide (Amorphous & Form B)
Oncology
Disclaimer
No information on this website, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patents Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including, patent scenario in their respective markets and will be responsible for all patent related liabilities Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.
